F. Tsuji

Safety and efficacy of first‐line dacomitinib in Japanese patients with advanced non‐small cell lung cancer

K. Wilner, M. Nishio, Toshiaki Takahashi, 2020, Cancer science.

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.

Ying Cheng, T. Mok, Yi-long Wu, 2017, The Lancet. Oncology.

Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial.

Ying Cheng, T. Mok, Yi-long Wu, 2017 .

ATLAS study: A randomized double-blind phase 3 study of adjuvant axitinib versus placebo in subjects at high risk of recurrent renal cell carcinoma (RCC).

H. Miyake, D. Quinn, D. Ye, 2014 .

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.

Ying Cheng, T. Mok, Yi-long Wu, 2017, The Lancet. Oncology.